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Dear Editor,
Data on the long-term efficacy of infliximab (IFX) in ulcerative colitis (UC) are scarce 
and there is limited evidence especially on sustained steroid-free remission and 
outcomes after IFX withdrawal. The ability of IFX to modify the course of the disease in 
the long-term, such as decreasing the need for surgery, remains questionable.1 After 10 
to 24 months of follow-up, retrospective studies report heterogeneous remission rates 
for UC between 17% and 90%.2-4 This wide range of remission may be due to the 
duration of IFX exposure, therefore affecting outcomes after IFX discontinuation. In 
small cohorts of 4 to 51 patients in remission, the rate of relapse following IFX 
discontinuation ranged from 0% to 59% after 6.5 months to 4.5 years of follow-up.2,5
This rate of relapse leads to difficult decision-making regarding maintenance therapy 
with IFX. 
We reviewed the medical charts of 100 patients treated with IFX for UC in a single 
gastroenterology unit between 2005 and 2012. Clinical remission was defined as a 
partial Mayo score of 2 points or lower, without bleeding; response, by a decrease of 2 
points; and relapse, by an increase of 2 points. Survival curves were estimated by the 
Kaplan–Meier method and compared using the log rank statistic. A Cox proportional 
hazards regression model was used to assess independent predictors of each event. 
Seventeen of the 100 patients were treated for acute, severe UC (refractory to 
intravenous steroids); 83, for steroid dependency or secondary to immunosuppressive 
therapy failure. In total, 52% of patients had concomitant immunosuppressive therapy at 
baseline.
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After a median duration follow-up of 55.1 months (IQR, 35.2-74.4), 35% of patients 
underwent surgery (median time from IFX initiation: 9.4 months). CRP>6 mg/L at week 
6 was the only independent factor associated with colectomy (HR=3.43, 95%CI, 1.17-
10.9; p=0.023). Sixty-four patients (64%) reached clinical remission after a median time 
of 20 weeks following IFX initiation (IQR, 6.5-47), and 28/64 (44%) relapsed during 
follow-up. The cumulative probabilities of sustained clinical remission at 1, 3 and 5 
years were 74, 52 and 39%, respectively. Based on standard clinical and biological 
parameters at IFX initiation and on the short-term outcomes, the independent factors 
associated with sustained clinical remission were: duration of IFX therapy >1 year 
(HR=2.61, 95%CI, 1.05-7.01; p=0.03), leukocyte count<10,000/mm3 (HR=2.18, 95%CI, 
1.02-4.77; p=0.04) and platelet count<400,000/mm3 (HR=2.77, 95%CI, 1.18-6.46;
p=0.02) at IFX initiation. Severe acute colitis at baseline did not influence long-term 
outcomes.
Finally, IFX was discontinued in 38/64 patients because of steroid-free clinical 
remission. After a median follow-up of 54 months (IQR, 25.4-64.5) following IFX 
withdrawal, 4/38 patients underwent colectomy (10%), 24 relapsed (63.2%), and 14
remained in clinical remission (36.8%). The cumulative probabilities of relapse after IFX
discontinuation were 24%, 61% and 81% at 1, 3 and 5 years, respectively (Figure 1). 
Based on univariate and multivariate analyses, age<21 years at diagnosis (HR=12, 
95%CI, 2.77-58.24; p=0.001) and a platelet count>400,000/mm3 at IFX withdrawal 
(HR=6.68, 95%CI 1.55-30.82; p=0.011) were associated with relapse. Continuous use 
of thiopurines following IFX withdrawal did not modify patient outcome and was not 
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associated with sustained clinical remission (p=0.29) or relapse (p=0.61) or with disease 
extent and disease severity at baseline.
In conclusion, after a 5-year follow-up IFX discontinuation in UC patients led to a high 
rate of relapse and was inversely associated with sustained remission. In our series,
one-third of patients underwent colectomy, one-third relapsed and only one-third 
experienced a sustained clinical remission. These results support the use of long-term 
IFX maintenance therapy in these patients.
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Figure Legend
Figure 1: Cumulative probabilities of relapse after infliximab discontinuation in ulcerative 
colitis patients in steroid-free clinical remission.
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